Biomarkers of browning of white adipose tissue and their regulation during exercise- and diet-induced weight loss\textsuperscript{1, 2}

Asif Nakhuda,\textsuperscript{3} Andrea R Josse,\textsuperscript{4} Valentina Gburcik,\textsuperscript{5} Hannah Crossland,\textsuperscript{6} Frederic Raymond,\textsuperscript{7} Sylviane Metaïron,\textsuperscript{7} Liam Good,\textsuperscript{8} Philip J Atherton,\textsuperscript{5} Stuart M Phillips,\textsuperscript{6} and James A Timmons\textsuperscript{5}* \textsuperscript{8}

\textsuperscript{3}School of Medicine, Derby Royal Hospital, University of Nottingham, Nottingham, United Kingdom; \textsuperscript{4}Department of Kinesiology, Brock University, St. Catharines, Canada; \textsuperscript{5}Royal Veterinary College, London, United Kingdom; \textsuperscript{6}Division of Genetics and Molecular Medicine, King’s College London, London, United Kingdom; \textsuperscript{7}Functional Genomics, Nestle Institute of Health Sciences, Lausanne, Switzerland; and \textsuperscript{8}Exercise Metabolism Research Group, McMaster University, Hamilton, Canada

ABSTRACT

A hypothesis exists whereby an exercise- or dietary-induced negative energy balance reduces human subcutaneous white adipose tissue (scWAT) mass through the formation of brown-like adipocyte (brite) cells. However, the validity of biomarkers of brite formation has not been robustly evaluated in humans, and clinical data that link brite formation and weight loss are sparse.

Objectives: We used rosiglitazone and primary adipocytes to stringently evaluate a set of biomarkers for brite formation and determined whether the expression of biomarker genes in scWAT could explain the change in body composition in response to exercise training combined with calorie restriction in obese and overweight women (n = 79).

Design: Gene expression was derived from exon DNA microarrays and preadipocytes from obesity-resistant and -sensitive mice treated with rosiglitazone to generate candidate brite biomarkers from a microarray. These biomarkers were evaluated against data derived from scWAT RNA from obese and overweight women before and after supervised exercise 5 d/wk for 16 wk combined with modest calorie restriction (≈0.84 MJ/d).

Results: Forty percent of commonly used brite gene biomarkers exhibited an exon or strain-specific regulation. No biomarkers were positively related to weight loss in human scWAT. Greater weight loss was significantly associated with less uncoupling protein 1 (UCP1) messenger RNA (which is expressed at KINGS COLLEGE LONDON on September 22, 2016ajcn.nutrition.org Downloaded from http://ajcn.nutrition.org/content/suppl/2016/08/03/ajcn.116.132563.DCSupplemental.html expression at KINGS COLLEGE LONDON on September 22, 2016ajcn.nutrition.org Downloaded from http://ajcn.nutrition.org/content/suppl/2016/08/03/ajcn.116.132563.DCSupplemental.html expression at KINGS COLLEGE LONDON on September 22, 2016ajcn.nutrition.org Downloaded from http://ajcn.nutrition.org/content/suppl/2016/08/03/ajcn.116.132563.DCSupplemental.html expression at KINGS COLLEGE LONDON on September 22, 2016ajcn.nutrition.org Downloaded from http://ajcn.nutrition.org/content/suppl/2016/08/03/ajcn.116.132563.DCSupplemental.html expression at KINGS COLLEGE LONDON on September 22, 2016ajcn.nutrition.org Downloaded from http://ajcn.nutrition.org/content/suppl/2016/08/03/ajcn.116.132563.DCSupplemental.html expression at KINGS COLLEGE LONDON on September 22, 2016ajcn.nutrition.org Downloaded from http://ajcn.nutrition.org/content/suppl/2016/08/03/ajcn.116.132563.DCSupplemental.html
be due to brite formation (10) and be part of the antidiabetic action of exercise (11). Similar to the situation of a negative energy balance encountered during cold stress in mice (12), it is plausible that the neuroendocrine recruitment of UCP1 activity occurs after an exercise-related negative energy balance. Nonetheless, to our knowledge, there have not been any previous larger-scale clinical studies that have confirmed this proposition, and the global molecular profile of human adipose tissue after exercise training or weight loss has also been understudied. To facilitate a successful pursuit of these concepts, novel molecular targets to promote the formation of brite cells and more-extensively validated biomarkers are required.

Rosiglitazone, which is a peroxisome proliferator–activated receptor-γ (PPARγ) agonist (13), is one of the few drugs used in humans that have been proven to generate brite adipocytes from white preadipocytes and even from the most developmentally white of adipose depots (epididymal) (2, 12), thereby suggesting that the PPARγ agonism is central to brite formation (14). Studies of how rosiglitazone mediates brite formation from white preadipocytes (2) have relied on a focused set of molecular markers (15) with limited technical validation. To extend this work, we used exon DNA microarray data (16) to better evaluate which RNA biomarkers of brite formation are likely to be most useful. Exon-based DNA microarray data have originated from mouse strains with a differential propensity for obesity (Sv/129 and C57BL/6). An analysis of the global transcriptome response to rosiglitazone could also potentially identify non-PPARγ ligands that might also promote brite formation (17). We applied a subset of stringent brite biomarkers to a large human study of subcutaneous white adipose tissue (scWAT) before and after exercise combined with modest calorie restriction to induce fat loss to determine the relation between weight loss and the regulation of genuinely stringent brite marker in vivo in humans.

METHODS

Human tissue and DNA microarray experiment data

Participants for our human study were from our previously published Improving Diet, Exercise and Lifestyle for women study (18, 19) (clinicaltrials.gov; NCT00710398) that was approved by the Research Ethics Board of the Hamilton Health Sciences and conformed to the most-recent Canadian government...
tricouncil funding policy statement on the use of human subjects in research. Biopsies were obtained from 85 overweight subjects before and after 16 wk of exercise training coupled with an ~20% reduction in daily energy requirements of which 79 subjects passed standard quality-control methods. All microarray samples from 79 subjects were used to filter the chip data (without background subtraction). A normalized with the use of quantile normalization, and detection calls were computed.

Analysis was carried out using R (version 3.2.2). Raw array data were deposited in the Gene Expression Omnibus database as GSE58559 and gene-chip data ([73]).

In Supplemental Table 1 and postsamples, which left 18,747 genes in the analysis (yielding a 5-mm Bergstrom) were taken from scWAT just above the vastus lateralis muscle of the quadriceps before and after the training intervention. RNA was extracted with the use of an Agencourt RNAdvance Tissue Kit (Beckman Coulter). A total of 300 ng was amplified with the use of an Illumina TotalPrep-96 RNA amplification kit (Life Technologies), hybridized to a HumanHT-12 V4.0 Expression BeadChip (Illumina), and scanned with the use of a BeadArray Reader (Illumina) (at Nestle Research Center). Samples from 79 subjects passed standard quality-control methods. All microarray analysis was carried out using R (version 3.2.2). Raw array data were normalized with the use of quantile normalization, and detection calls were used to filter the chip data (without background subtraction). A median P value of 0.1 was used for detection rates across presamples and postsamples, which left 18,747 genes in the analysis (yielding a detected-gene count that was similar to the count in previous studies).

Quantitative significance analysis of microarrays [using the SAMR package (Stanford University) in R, where the quantitative option in false discovery rate (FDR) adjusted correlative model] was implemented to generate a list of genes that vary in a positive or negative manner with weight loss (FDR <10%). Pearson correlation coefficients were calculated independently. Microarray data were deposited in the Gene Expression Omnibus database as GSE58559 (National Center for Biotechnology Information).

Cell culture, drug treatment, and RNA profiling

Subcutaneous inguinal preadipocytes were isolated from Sv/129 or C57BL/6 mice (Harlan) and processed as previously described (20–22). Where indicated, cells were supplemented with or without 1 µmol rosiglitazone maleate/L (Enzo Life Sciences) from the first day of culture (20). RNA was extracted on day 7 with the use of TRIzol solution (Life Technologies) as previously described (1). RNA was dissolved in 20 µL RNAse-free water and stored at −80°C for subsequent analysis as previously described (16). Sets of independent adipocytes cultures were produced for RNA for use in the reverse transcriptase–quantitative polymerase chain reaction (RT-qPCR) studies. A total of 500 ng total RNA was reversed transcribed with a High-Capacity cDNA Reverse Transcription kit (Life Technologies). Complementary DNA was diluted 1:5, and

FIGURE 2 Establishment of reliable brite markers. The Affymetrix Exon ST 1.0 (Affymetrix) arrays that were used for pathway enrichment (Figure 1B) also provided exon-level changes that occurred with ROSI in detectable genes and were used to extract specific expression values corresponding to primers used in de Jong et al. (15) to calculate the mean ± SD percentage of change in expression in response to ROSI (n = 9) from the control (n = 8). All phenotypic adipocyte markers except for Cidea (which is not a valid adipocyte subtype marker in humans (9)) were measured. Only phenotypic adipocyte markers that reached significance are shown, whereas remaining phenotypic adipocyte-marker data are shown in Supplemental Figure 1. Expression changes from de Jong et al. (15) are shown and were estimated from the original publication that used NMRI mice (15), which indicated that not all brite markers share the same directionality across studies. Student’s unpaired t test was performed with the use of linear expression intensities.

FIGURE 3 Effects of 16 wk of exercise and dieting on body composition. Subjects from Josse et al. (18, 19) were all premenopausal and overweight or obese women, and an overview of clinical characteristics is shown in Supplemental Table 2. Body-composition data (measured with the use of dual-energy X-ray absorptiometry) from each subject (with complete biopsies and body-composition data) were compared before and after the intervention and led to significant fat mass loss (A) and total body weight loss (B). Data are shown for all subjects (n = 79). Each dot and its respective connected dot represent data from a single subject. Student’s paired t test was performed; ****P < 0.0001.
performed with the use of linear expression intensity (AU), but no significance
categories were not included.

hit multiple genomic regions, and thus, genes that fall into either of these cate-
genes identified in mice had one-to-one orthologs, and certain Illumina probes
ROSI genes (C) changed with intervention. Note that not all ROSI-responsive
but neither the most-upregulated ROSI genes (B) nor the most-downregulated
regulated genes were measured in human subcutaneous white adipose tissue,
changes were shown. Note that

in 79 individuals before and after a 16-wk intervention. The data set was used to
Expression BeadChip (Illumina) were used to measure gene-expression changes
in mouse epididymal adipose tissue in response to exercise and dieting. HumanHT-12 V4.0
Expression BeadChip (Illumina) were used to measure gene-expression changes
in 79 individuals before and after a 16-wk intervention. The data set was used to
extract mean ± SD linear expression intensities corresponding to brite markers
(A) that were consistent across Sv/129, C57BL/6, and NMRI mice, but no
changes were shown. Note that CA4 is the human ortholog of Car4. ROSI-
regulated genes were measured in human subcutaneous white adipose tissue,
but neither the most-upregulated ROSI genes (B) nor the most-downregulated
ROSI genes (C) changed with intervention. Note that not all ROSI-responsive
genes identified in mice had one-to-one orthologs, and certain Illumina probes
hit multiple genomic regions, and thus, genes that fall into either of these cate-
gories were not included. n = 79 paired samples. Student’s paired t test was
performed with the use of linear expression intensity (AE), but no significance

Exon DNA microarray production

Twenty Affymetrix Murine Exon 1.0 ST arrays (Affymetrix) were processed as previously described (16). Three samples were
excluded as outliers by normalized unscaled SE plots (supported by a principal component analysis) before any downstream
statistical analysis was conducted. The raw data have been deposited in the Gene Expression Omnibus database as GSE57903,
and these data have been used to develop a novel bioinformatic method for analyzing gene splicing (16). An update of the annotation
of the exon array resulted in 16% of probes being removed because of cross-hybridization at multiple genomic loci. Subsequently,
10% of probe sets were removed because the signal was approximately background across all samples. Finally, the remaining probe
sets (74% of all core probe sets) were mapped to a unique gene identifier and significance analysis of microarrays was used to
estimate rosiglitazone-mediated differentially expressed genes in Sv/129 and C57BL/6 cells. To allow for an accurate meta-
analysis of brite phenotypic adipocyte markers between our study (Sv/129 or C57BL/6 mice) and published data from studies using
Naval Medical Research Institute (NMRI) mice (15), microarray probe sets were selected to precisely match the regions spanned by
primers in the mentioned study (15) by using the Primer-BLAST tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).

Biological pathway analysis and upstream regulator
analysis

Regulated genes used for pathway and gene ontology analysis need to be adjusted for technology and biological bias (23). To
partially address this, the group of regulated genes was contrasted with all detectable genes in the experiment (and not with all genes
on the gene chip or in the network database). An ingenuity pathway
analysis (IPA) was used to identify potential upstream regulators of
the regulated gene list, whereby regulated and background detect-
table genes were mapped to an IPA database (17). We used an
upstream analysis whereby a P value was generated on the basis

was shown. B3GALT2, beta-1,3-galactosyltransferase 2; CA4, carbonic an-
hydrate 4; CIDEC, cell death inducing DFFA like effector c; ELOVL3, fatty acid
elongase 3; EVA1, epithelial V-like antigen 1; FABP3, fatty acid binding protein 3;
FGF21, fibroblast growth factor 21; GABRE, gamma-aminobutyric acid type A
epsilon subunit; GTS2, glycerone synthase 2; HPSE, heparanase; HSD11B1, hy-
droxysteroid 11-beta dehydrogenase 1; IL6, interleukin 6; IL1RL1, interleukin 1
receptor like 1; LHX8, LIM homeobox 8; NAT8L, N-acetyltransferase 8 like;
NMRI, naval medical research institute; PAT2, proton/amino acid transporter 2;
PRDM16, PR domain containing 16; P2RX5, purinergic receptor P2X 5; ROSI,
rosiglitazone; SERTPINB2, serpin family B member 2; SLC16A3, solute carrier
family 16 member 3; SPTLC3, serine palmitoyltransferase, long chain base
subunit 3; UCP1, uncoupling protein 1.
of the degree of overlap between a given gene set within the IPA database (which typically reflects the published gene changes in response to a range of transcription factors or drugs) and the differentially expressed genes in the current data. After adjusting for the data-set size, a Fisher’s exact test was applied. A second variable [activation or inhibition (z score)] was used to compare the directional change in the experimental gene set compared with in the IPA database. The z score informed on whether the upstream regulators were likely to be active or inhibited. A z score ≥2 and a robust P value (e.g., P < 1 × 10⁻³ or better) were required to consider an association as being significant and, thus, potentially of biological interest.

Statistical analysis

All nonmicroarray statistics were carried out with the use of GraphPad Prism software (version 6.0; GraphPad Software). For the RT-qPCR analysis, a Mann-Whitney U test was performed with the use of a Δcycle threshold value between the control group and the rosiglitazone group. For the murine analysis, an unpaired t test was performed with the use of linear-expression values from exon-specific probe sets between control and rosiglitazone groups. For the human analysis, a paired t test was performed on values of total body weight, fat mass, and linear expression from probe sets before and after the intervention. Pearson correlation coefficients were derived between the change in weight and the change in gene expression with the intervention.

RESULTS

The rosiglitazone treatment resulted in substantial differential gene expression (Supplemental List 1). In C57BL/6-derived white adipocytes, the rosiglitazone treatment resulted in 1270 and 736 genes being upregulated and downregulated, respectively. In Sv/129 adipocytes, 833 and 308 genes were upregulated and downregulated, respectively. RT-qPCR validation confirmed similar Fabp4- and Ucp1-expression changes in both strains (Supplemental Table 2) showed that both Sv/129 and C57BL/6 gene lists were dominated by an extremely strong rosiglitazone-related transcriptional signature (Sv/129: z = 5.8, P = 1.2 × 10⁻²³; C57BL/6: z = 6.5, P = 3.7 × 10⁻³⁰) that was consistent with a PPARγ-activation signature (Sv/129: z = 5.7, P = 1.63 × 10⁻²⁵; C57BL/6: z = 5.9, P = 4.16 × 10⁻²⁹). This analysis provided robust experimental validation of the upstream-analysis method for subsequent use with the human clinical data.

Various brite phenotypic biomarkers along with other genes measured by de Jong et al. (15), which relied on NMRI mice, were shown to be ~60% consistent with Sv/129 and C57BL/6
mice (Supplemental Table 3). In our study, 12 of the biomarkers were significantly altered with rosiglitazone, but not all biomarkers were regulated in the same direction as noted in NMRI mice [e.g., homeobox C9 (Hoxc9), F-box protein 31 (Fbxo31), zinc-finger protein of the cerebellum 1 (Zic1), and homeobox C8 (Hoxc8) (in the current study, Zic1 decreased with rosiglitazone) (Figure 2)]. Several additional phenotypic marker genes did not respond to rosiglitazone, including cluster of differentiation 137 (Cd137), transmembrane protein 26 (Tmem26), and cebp/p300-interacting transactivator 1 (Cited1) (Supplemental Figure 1A) indicating that they may be markers of cell origin. In addition, the exon-specific RNA profiling of LIM homeobox 11 (Lhx8), purinergic receptor P2X 5 (P2rx5), and alanine-serine-cysteine 1 (AsString) showed that an interpretation of rosiglitazone’s effects was dependent on which exon was selected for the RT-qPCR analysis (Supplemental Figure 2A). An analysis of house-keeping gene responses across strains (15) showed that this dependence did not explain differences across studies (Supplemental Figure 1B).

The stringent biomarker genes, which reflected the exon-level analysis of the in vitro brite-formation studies, were checked to ensure comparability with the 3’ end of the same transcripts (data not shown) because the responses of these genes in human scWAT were measured with the use of a standard 3’ DNA microarray. As previously published (18, 19), there were substantial improvements in body composition after this gold-standard lifestyle intervention with a loss of fat mass (−4.4 ± 2.8 kg; P < 0.0001) and total body mass (−4.4 ± 3.5 kg; P < 0.0001) (Figure 3). However, we showed no evidence for the positive regulation of any brite marker gene in human scWAT in response to exercise and dieting (P > 0.05) (Figure 4A).

In addition, the human adipose tissue gene-expression response to exercise training and calorie restriction was not related to the pattern of rosiglitazone-regulated genes (Figure 4B, C). When we correlated the extent of weight loss with changes in selected brite markers or rosiglitazone-regulated genes, we found that UCP1 (P = 0.006, R2 = 0.09) (Figure 5A) and N-acetyltransferase 8 like (NAT8L) (P = 0.03, R2 = 0.11) (Figure 5B) were decreased with greater weight loss (i.e., the opposite direction that was expected if brite formation was occurring), whereas fibroblast growth factor 21 (FGF21) showed no correlation (Figure 5C).

An unbiased DNA microarray analysis of human scWAT in response to the intervention showed 155 RNAs were positively correlated with weight loss and 26 RNAs were negatively correlated with weight loss (FDR <10%) (Supplemental List 2). An example of a gene that was univariately correlated with weight loss (TNFRSF21) is shown in Figure 5D (R2 = 0.22, P < 0.0001). After updating the 181 genes and the detected background genes into the IPA database (Supplemental List 3), 161 genes were available for analysis. These weight-loss–correlated genes showed enrichment in the expected pathways such as lipid metabolism (Supplemental Figure 3) as well as evidence for dynamic tissue remodeling including adipogenesis rather than a simplistic atrophy of adipose tissue mass (Supplemental Table 4). For instance, we showed evidence for CCAAT/enhancer binding protein α (C/EBPα) activation (z = 2.0, P = 6.6 × 10−7) that was indicative of adipogenesis (Figure 6). We also noted a marginal result of interest (less than the stated z = 2 threshold) [i.e., adenosine A2 activation (z = 1.9, P = 7.9 × 10−5)] upstream of some of the transcriptional responses in scWAT during weight loss. More-robust results included evidence for liver X receptor α/β (LXRα/β) agonism (z = 2.1, P = 2.8 × 10−7) and the inhibition of leptin-like signaling (z = −2.6, P = 3.9 × 10−5).

**DISCUSSION**

In the current study, we discovered that UCP1 expression was negatively correlated with weight loss in humans in response to exercise training combined with modest energy restriction. Our data appear to rule out the hypothesis that exercise promotes weight loss through brite formation (10) at least in women and when a negative energy balance is induced via a combination of strategies. The study of the molecular drivers that regulate the WAT phenotype, including the promotion of the formation of brite adipocytes, is a complex process that requires both in vitro and in vivo models (24). Brite formation has been proposed as a mechanism to increase the metabolic rate to promote weight loss in obese subjects (10). Several factors limit the progress toward the testing of this hypothesis including a lack of novel drugs to stimulate brite formation. In addition, knowledge of reliable biomarkers for brite formation that are consistent in both preclinical and clinical models are needed (i.e., for drug-development studies).
The upstream analysis showed that rosiglitazone-treated cells displayed a clear pattern of gene expression that reflected PPARγ agonism (Supplemental Table 2). We also showed that the rosiglitazone transcriptional signature was strongly linked to mono((2-ethylhexyl)phthalate (MEHP) activity ($z = 5.6, P = 2.7 \times 10^{-31}$). An environmental obesogen, MEHP originates from plastics and, after either in vitro or in utero exposure, promotes adipogenesis (25). The impact of MEHP on brite formation is unknown, but the presence of this common environmental factor complicates the interpretation of UCP1 expression analyses in adult humans. Mimicking global aspects of PPARγ agonism, MEHP has a PPAR co-activation activity (26, 27). Although phthalate metabolites have been associated with increased diabetes risk, MEHP has not (28), which suggests that a greater understanding of the molecular actions of MEHP may yield insight into how to safely promote brite formation.

We were able to identify a number of compounds that partially overlap with the brite gene-expression program. The P38 mitogen-activated protein kinase inhibitor SB203580 was significantly associated with the rosiglitazone signature ($z = 4.69, P = 6.8 \times 10^{-14}$) as was PD98059, which is an indirect extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor ($z = 6.15, P = 2.1 \times 10^{-12}$). Holstrom et al. (29) showed that Erk1/2 activation was involved in the initial proliferation response in brown pre-adipocytes. U0126, which is another indirect inhibitor of ERK1/2, which also appeared important for activating an adipogenic program in human mesenchymal stem cells (30). The global rosiglitazone transcriptional signature also overlapped with mitogen-activated protein kinase kinase kinase 4 (MAP2K4) inhibition ($z = -5.05, P = 4.8 \times 10^{-27}$). MAPK4 was subject to a drug-discovery effort, and the silencing of Map4k4 induces Myf5, which is a developmental muscle and brown-adipocyte cell marker (31). We suspect that it is unlikely that MAP4K4 inhibitors have a sufficient safety profile to represent a chronic strategy for promoting brite formation (32). However, single-target drugs for complex chronic diseases are also unlikely, and it would be more appealing to consider combinatorial therapy options, e.g., combined ERK activation and MAP4K4 inhibition targeting distinct components of the rosiglitazone RNA-expression program.

Although a variation in the extent of the browning response in different scWAT depots is accepted, the issue of variation can be extended by consideration of both the genetic background (33) and transcript variants (the exon targeted for RT-qPCR) of each phenotypic marker. Some phenotypic markers have an unclear biological role during browning, whereas some markers such as Fgf21 are thought to actively influence thermogenesis (34). The adipocyte markers described in the current study are representative of markers that have been commonly used in literature (15). One recent study claimed to determine the stringency of brite markers with the use of NMRI mice (15). We revisited these data (15) (Supplemental Table 3), and in general terms (directionality), there was only an ~60% agreement between studies. Although the use of different messenger RNA quantification methods (RT-qPCR compared with microarray) can introduce differences, exon arrays allowed us to match the exon and housekeeping-gene analyses across studies (Supplemental Figure 1B). However, with the use of a subset of stringent brite biomarkers, we showed no regulation in adipose women in a negative–energy-balance state. The current repertoire of murine-derived phenotypic adipocyte markers may need to be superseded by human studies; however, efforts to profile human adipose tissue (35) must control for the presence of contaminating cell types (i.e., blood, blood vessels, and nerves). There are also limitations of our in vitro models (2, 20, 21) because we do not fully capture the complexity of brite formation or adipose tissue dynamics in vivo, and thus, specific markers in the context of an in vitro system can become nonspecific in a human tissue biopsy.

Increasingly, it has become accepted that chronic exercise training should alter the phenotype of adipose tissue and not just reduce its mass (10). If exercise training induced greater UCP1 activity, this effect might represent a counterintuitive increased capacity for heat generation (rather than dissipation). In contrast, excessive adipose tissue loss reduces the role of human adipose tissue in thermal insulation, and perhaps a greater thermogenic capacity would have been beneficial for survival (but now we have clothes and central heating). Nevertheless, we observed that human scWAT samples did not show signs of browning with 16 wk of exercise training despite marked improvements in fitness, fat loss, and the identification of specific molecular programs that are related to the remodeling of adipose tissue. We noted a decrease in UCP1 expression with weight loss, which was perhaps an adaptive response (whitening) that reflected reduced calorie intake or a negative energy balance. We note that UCP1 expression can be lower in leaner individuals (9), which suggests that our finding is not paradoxical, at least in humans. However, a potential limitation of this study was the lack of a comparative energy-restriction-only group to determine the contribution of reduced calorie intake on scWAT. In addition, our study consisted of women, and we only assessed one scWAT region.

Emerging studies on WAT biology have been primarily focused on understanding mechanisms that transform WAT to energy-dissipating tissue (10). However, a greater understanding of molecular adaptations concomitant with weight loss will provide insights in understanding WAT plasticity and health. The loss in adipose mass with exercise has been commonly reported to reflect reduced adipocyte size (36), and whether the adipocyte number changes is not often reported with exercise. Our molecular network analysis showed evidence that there was increased C/EBPβ activity in the tissue, which was concurrent with exercise- and diet-induced weight loss, and such activity is typically associated with adipogenesis. Therefore, it would seem that our intervention may have increased adipocyte turnover because the total adipocyte number remains roughly stable with weight loss (37).

We showed evidence for the inhibition of local adipose leptin signaling as well as LXRα/β agonism. Previous studies have showed that, when human white adipocytes are treated with an LXR agonist, there is an increased lipolysis and β oxidation (38). With the use of an IPA, we identified an intriguing overlap with 11 genes that we previously showed (39) were related to the ability to remodel the cardiovascular capacity, thereby suggesting that these adaptability genes may influence the potential to remodel multiple tissue (4 11 genes; Benjamini-Hochberg–corrected $P = 5 \times 10^{-4}$).

In conclusion, with the use of a genuinely stringent repertoire of brite biomarkers in human scWAT samples, 16 wk of exercise training with calorie restriction does not result in increased UCP1 expression or of any other brite biomarker despite evidence for the molecular remodeling of adipose tissue.
We thank Natasa Petrovic, Jan Nedergaard, and Barbara Cannon for their contribution to the design of the rosiglitazone gene-chip experiment in 2010. The authors’ responsibilities were as follows—AN: carried out RT-qPCR experiments and reviewed the biological literature; AN and JAT: carried out the bioinformatic analysis and drafted the manuscript; ARJ: oversaw the design, data collection, and training for the Improving Diet, Exercise and Lifestyle study; VG and LG: helped design and carry out the cell culture experiments; HC and PJA: helped draft and edit the manuscript and provided supervision of the RT-qPCR analysis; FR and SM: carried out the Illumina-microarray experiment; PJA and SMP: edited the manuscript; SMP: designed the Improving Diet, Exercise and Lifestyle study and helped analyze its data; JAT: conceived the study idea and design and carried out the Affymetrix-microarray experiment; and all authors: read and approved the manuscript for publication. LG and JAT are shareholders in XRGenomics Ltd., but this project was not linked to the commercial interests of the company. The remaining authors reported no conflicts of interest related to the study.

REFERENCES


